23 Feb 2021 | News
Gabriel says gap between programmes will be ‘narrow’
EU research commissioner vows to avoid interruptions in the flow of EU R&D funding amid delayed rollout, as she outlines plan for stricter rules for international research cooperation, to reflect ‘geopolitical changes’
Mariya Gabriel, EU commissioner for research and innovation. Photo: EU Commission.
EU commissioner Mariya Gabriel kicked off the Science|Business conference on Monday with a promise that despite the late start to Horizon Europe there will be no interruption in EU research funding.
The first €120 million Horizon Europe call for collaborative research into emerging COVID-19 variants will launch in March, through an emergency procedure. “The gap between programmes will be very narrow,” said Gabriel, noting the last Horizon 2020 call closed as recently as January.
E-Mail
SILVER SPRING, Md. A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. These exciting results suggest that there may be a novel mechanism for achieving weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits, said Steve Heymsfield, MD, FTOS, past president of The Obesity Society and corresponding author of the study. Heymsfield is professor and director of the Metabolism and Body Composition Laboratory at the Pennington Biomedical Research Center in Baton Rouge, La.